Bionano Genomics Appoints Alex Hastie as CSO to Accelerate OGM Clinical Growth
BNGO•Bionano Genomics has appointed Alex Hastie, Ph.D., as Chief Scientific Officer effective July 20, 2026. Hastie’s 14 years of experience developing optical genome mapping will guide the company’s global scientific strategy, innovation roadmap and expansion of clinical applications in cytogenomics, oncology and rare disease research.
1. Appointment of Chief Scientific Officer
Bionano Genomics has named Alex Hastie, Ph.D., as Chief Scientific Officer, effective July 20, 2026. In his new role, Hastie will oversee the company’s global scientific strategy and innovation roadmap, emphasizing the development and deployment of optical genome mapping (OGM) solutions.
2. Hastie’s Background and Contributions
Hastie was a foundational figure in Bionano’s scientific evolution, spending 14 years advancing OGM technology across cytogenomics, oncology and rare disease research. His prior work includes developing core platforms and establishing Bionano’s leadership in ultra-high molecular weight DNA isolation, structural variant analysis and interpretation.
3. Strategic Focus and Expected Impact
As CSO, Hastie will drive expansion of clinical research collaborations, accelerate evidence generation and translate OGM into broader applications. His return is expected to strengthen Bionano’s scientific leadership, improve scalability and robustness of OGM solutions, and support growth in clinical and translational genomics markets.
